Senior Medical Science Liaison高级医学科学联络官
付许伟
Lucas Fu
让复杂的临床证据，成为临床实践中
可被理解与使用的知识。
外科学硕士，骨外科主治医师出身。从手术台到证据链，我关心的始终是同一个问题——研究如何真正改变临床决策。
Fig. 01 — Kaplan–Meier Estimate
Illustrative
21
国际会议成果
2022 — 2026
2022 — 2026
21
会议成果
ASCO · ESMO · ESMO Asia · SABCS · CSCO
8
全文发表
国际同行评议期刊
6+
年肿瘤 MSL
乳腺癌 · 肝胆 · 肺癌
3
地 KOL 网络
河北 · 天津 · 山西
01Profile · 专业概览
以证据为语言，
连接科学与临床。
我是付许伟。比起急着给出答案，我更习惯先问：这个病人真正需要什么？证据又能回答什么？做 MSL 的这些年，我一直在练习把这两个问题接起来。
我的工作围绕临床研究设计、统计分析与证据转化展开：用 R、Python、SAS 处理临床试验与真实世界数据，也把大模型引入文献综述、证据表构建和分析流程。从乳腺癌、肝胆肿瘤到肺癌，治疗领域在变，但研究设计、统计判断与学术表达的方法是相通的。
i
临床研究设计
从科学问题到可执行的研究方案
ii
统计与 AI
生存分析、真实世界证据与 AI 工作流
iii
学术传播
Poster、病例报告与全文发表
Career · 职业履历
2020 — Now · 河北 / 天津 / 山西
-
2026.03 — 至今
翰森制药 Hansoh
肺癌领域 · SrMSL
河北 · 山西 · Base 石家庄
-
2024 — 2026
阿斯利康 AstraZeneca
肝胆肿瘤 · MSL
河北 · 天津 · Base 石家庄
-
2020 — 2024
恒瑞医药 Hengrui
乳腺癌 · MSL
河北 · 天津 · Base 石家庄
02Expertise · 专业能力
方法、工具
与表达。
从研究设计、统计分析到学术表达与 AI 工作流，以下四组能力覆盖日常工作的主要环节。
01
临床研究
Clinical Research- 研究设计95
- 方案撰写92
- CRF 设计88
02
统计分析
Biostatistics- Python / R92
- 样本量计算88
- 数据可视化90
03
学术技能
Academic Craft- 论文撰写92
- Poster 制作94
- 数据解读93
04
AI 应用
AI & Automation- Skills 工程88
- Agent 工程86
- 自动化90
03Research · 学术成果
发表在
证据之中。
2022 年以来，8 篇全文论文发表于国际同行评议期刊，21 项成果入选 ASCO、ESMO、ESMO Asia、SABCS 与 CSCO。
全文发表 Journal Articles
08Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial
The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial
Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2− advanced breast cancer
Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study
Dalpiciclib plus fulvestrant and pyrotinib in HR+/HER2-low advanced breast cancer after progression on CDK4/6 inhibition (DapPLE-HER): a Bayesian optimal phase II study
Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2− stage II–III breast cancer (DARLING 01)
会议成果 Congresses
21按最新年份排列，点击会议条目可展开全部入选成果与官方链接。
2026
- YO CaseMissed Truncal EGFR Exon 19del on Pleural Fluid NGS After Exceptional Chemo-IO Response: Long-Term Cerebrovascular Safety of Late-Line Aumolertinib in High-Risk NSCLCFPN: YO25
2025
2024
- TPSA phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR-positive HER2-negative breast cancer: DARLING-02
- TPSNeoadjuvant dalpiciclib, exemestane, and goserelin in premenopausal women with HR-positive, HER2-negative breast cancer
- AbstractEfficacy and safety of dalpiciclib, fulvestrant, and pyrotinib in HR+ HER2-low advanced breast cancer following CDK4/6 inhibitors and AIs
- AbstractEfficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer
- TiPOsimertinib combined with dalpiciclib in EGFR-mutant, CDK4/6 pathway-altered advanced NSCLC patients with acquired resistance to third-generation EGFR-TKIs
- PosterEfficacy and safety of dalpiciclib, exemestane, and goserelin as neoadjuvant therapy in premenopausal HR-positive, HER2-negative breast cancer patients
2023
2022
- PosterPyrotinib in combination with metronomic oral vinorelbine in patients with HER2-positive advanced breast cancer who had failed prior trastuzumab-based therapy
- PosterPyrotinib-based therapy for patients with HER2-positive breast cancer: a multicenter, real-world study
- PosterA phase 3, multicenter, open, randomized controlled study of gemcitabine plus capecitabine versus gemcitabine plus carboplatin in first-line advanced triple-negative breast cancer
- AbstractApatinib plus etoposide as second- or higher-line treatment in recurrent or metastatic triple-negative breast cancer
- AbstractEffect of traditional Chinese medicine on pyrotinib-associated diarrhea in patients with HER2-positive breast cancer
- AbstractPyrotinib combined with EC-TH neoadjuvant therapy for patients with HER2-positive breast cancer
04Voices · 同行评价
来自合作医院的
专业认可。
以下评价来自此前乳腺癌合作中的河北、天津临床专家。
05Contact · 联系
让研究回到
临床问题本身。
欢迎医院、学会与行业伙伴就临床研究设计、真实世界证据、AI 辅助证据工作流与学术传播交流合作。
931928708@163.com